Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Operations: 2017-2025

Historic Cash from Operations for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to -$67.9 million.

  • Autolus Therapeutics' Cash from Operations rose 11.52% to -$67.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$254.2 million, marking a year-over-year decrease of 23.10%. This contributed to the annual value of -$206.3 million for FY2024, which is 41.68% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Cash from Operations of -$67.9 million as of Q3 2025, which was up 6.71% from -$72.8 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Cash from Operations ranged from a high of -$9.2 million in Q4 2021 and a low of -$76.7 million during Q3 2024.
  • For the 3-year period, Autolus Therapeutics' Cash from Operations averaged around -$55.9 million, with its median value being -$51.1 million (2024).
  • In the last 5 years, Autolus Therapeutics' Cash from Operations spiked by 31.97% in 2022 and then tumbled by 86.52% in 2025.
  • Over the past 5 years, Autolus Therapeutics' Cash from Operations (Quarterly) stood at -$9.2 million in 2021, then skyrocketed by 31.97% to -$30.8 million in 2022, then fell by 23.82% to -$38.1 million in 2023, then slumped by 33.91% to -$37.9 million in 2024, then grew by 11.52% to -$67.9 million in 2025.
  • Its last three reported values are -$67.9 million in Q3 2025, -$72.8 million for Q2 2025, and -$75.6 million during Q1 2025.